Talis Biomedical Corporation
General ticker "TLIS" information:
- Sector: Health Care
- Industry: Health Care Equipment & Supplies
- Capitalization: $2.9M (TTM average)
Talis Biomedical Corporation does not follow the US Stock Market performance with the rate: -9.1%.
Estimated limits based on current volatility of 0.2%: low 1.60$, high 1.61$
Factors to consider:
- Total employees count: 99 (-2.9%) as of 2023
- Top business risk factors: Economic downturns and volatility, Cybersecurity threats, Pandemic risks, Product liability, Labor/talent shortage/retention
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [3.57$, 10.91$]
- 2024-12-30 to 2025-12-30 estimated range: [2.13$, 7.07$]
Financial Metrics affecting the TLIS estimates:
- Negative: with PPE of -0.2 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -366.82 <= 0.33
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: -4.48 < Investing cash flow per share per price, % of -3.35
- Positive: Shareholder equity ratio, % of 73.00 > 63.39
Short-term TLIS quotes
Long-term TLIS plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $3.65MM | $0.41MM |
| Operating Expenses | $200.01MM | $116.36MM | $67.23MM |
| Operating Income | $-200.01MM | $-112.71MM | $-66.81MM |
| Non-Operating Income | $7.97MM | $-0.31MM | $4.81MM |
| R&D Expense | $157.59MM | $70.83MM | $40.69MM |
| Income(Loss) | $-192.04MM | $-113.01MM | $-62.01MM |
| Profit(Loss)* | $-190.46MM | $-113.01MM | $-62.01MM |
| Stockholders Equity | $233.98MM | $126.74MM | $69.12MM |
| Assets | $265.83MM | $169.29MM | $94.67MM |
| Operating Cash Flow | $-171.38MM | $-100.14MM | $-53.24MM |
| Capital expenditure | $2.87MM | $1.61MM | $0.49MM |
| Investing Cash Flow | $-2.87MM | $-1.61MM | $-0.49MM |
| Financing Cash Flow | $234.43MM | $0.41MM | $0.03MM |
| Earnings Per Share** | $-126.13 | $-63.65 | $-34.12 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.